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Abstract
Forty-nine male weight lifters, all users of anabolic-androgenic steroids (AASs), completed an anonymous,
self-administered questionnaire to investigate addictive patterns of use. At least one DSM-III-R symptom of
dependence was reported by 94% of the sample. Three or more symptoms, consistent with a diagnosis of
dependence, were reported by 57%. Dependent users (ii=28) could be distinguished from non-dependent users
(n=21) by their use of larger doses, more cycles of use, more dissatisfaction with body size, and more aggressive
symptoms. Multiple regression analysis revealed that dosage and dissatisfaction with body size were the best
predictors of dependent use. Patterns of other substances used, although not predictive of AAS dependence,
revealed very low cigarette use and at the same time high alcohol consumption. These data support the notion
that AASs are addicting, and suggest that dissatisfaction with body size may lead to dependent patterns of use.
The implications for both prevention and treatment are discussed.
Introduction symptoms of psychoactive substance dependence as
Anabolic-androgenic steroids (AASs), which in- defined by DSM-III-R." We now extend our
elude the male hormone, testosterone, and its findings to 49 male AAS users. Specifically, the
synthetic derivatives, are used illicitly to enhance objectives of the present study were to describe a
athletic performance, physical appearance, and community-based sample of male weight lifters who
fighting ability.''^ Several studies suggest that the admitted to taking AASs in terms of demographics,
use of AASs is associated with psychiatric symp- training characteristics, and patterns of AAS use; to
toms, such as increased aggression and mood determine the nature and frequency of dependency
disturbances.^"* Other reports suggest that AASs symptoms in the sample; and to determine if there
have addictive potential.'"'" The potential of AASs were particular demographic, pharmacologic, or
to cause addiction and other psychiatric effects psychological correlates of dependence on AASs.
implies that mental health and addiction profession-
als may increasingly see AAS users in practice.
We previously reported results of a pilot survey,'' M th d
in which all eight AAS users had experienced „ , .
Subjects were 49 male weight lifters who were
Correspondence to: Kirk Brower, Chelsea Arbor Treatment . j r ^ '^ • »
Center, 775 S. Main Street, Chelsea, MI 48118-1399, USA (Tel: KCruited from four community gymnasiums to
313-475-4100). Complete a self-administered questionnaire. In-
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formed consent was obtained in writing from the
gym owners or managers to distribute the question-
naire on-site. Owners/managers were assured that
the name of their gym and other identifying
information would be kept confidential. Four gym-
nasiums were selected because of their convenience,
and none refused participation.
Over a 7-month period ending in November
1989,449 questionnaires were collected from weight
lifters, including 45 females (10%). Because only
two female AAS users were identified, we excluded
women from the analyses. Of the 404 surveys from
men, 49 (12%) admitted to using AASs and
comprised the sample for this study.
The questionnaire
We developed a questionnaire specifically for this
study, entitled "The University of Michigan Weight
Lifter's Survey". Designed to be self-administered
in 15-20 minutes, it obtained information about
demographic variables, training characteristics, phy-
sical characteristics, body image, AAS and other
substance use, and consequences of AAS-taking.
Questions regarding symptoms of dependence on
AASs were modified from two existing structured
diagnostic instruments that are keyed to DSM-III-R
criteria.'^•'•'
Subjects were asked by research assistants to
complete the questionnaire either before or after
their workouts. The front page contained instruc-
tions that explained the purpose of the questionnaire
and gave assurance about anonymity. Subjects were
instructed not to put their names on the question-
naire. They placed the completed questionnaire
inside a provided envelope, sealed it, and deposited
it in a specially designated box. The questionnaires
were then removed from the gym and opened at a
later date by research staff, who did not know from
which gymnasium they came or who filled them out.
The validity of the questionnaire was tested in a
pilot sample by face-to-face interviews in five
subjects and urine testing in one subject. In all
tested instances, the information on the question-
naire was confirmed. In addition, reliability coeffi-
cients for two repeated questions in the question-
naire among the 49 subjects were high (Pearson
r=0.98,/)=0.0001 and r=0.83,/)=0.0001).
Variables of interest
We were first interested in describing our sample in
terms of demographics, training characteristics, and
patterns of AAS use. We were next concerned with
the type and frequency of DSM-III-R symptoms of
dependence that were reported. To examine depen-
dence as a syndrome, we divided our sample into
two groups. Those who endorsed three or more
DSM-III-R symptoms of dependence were classi-
fied as dependent, in accordance with the DSM-III-
R criteria for the diagnosis of dependence." Those
who endorsed less than three symptoms were
classified as non-dependent. We then compared
these two groups on variables that we thought might
either predict or correlate with dependence. These
variables could be classified into four major
domains: demographic, pharmacologic, psycho-
logical, and physical.
Most variables are self-explanatory, except for
those that follow. Among pharmacologic variables,
duration of AAS use was calculated as the number
of months between first and last use. Because
different individuals used different AASs with
differing potencies, a derived measure was created
to compare dosage across individuals. The mean
dose across individuals using a particular drug was
calculated, and each individual's dosage of that drug
was then converted to a standardized z-scott. The
individual's highest 2'-score among all drugs tried
was used as the measure of maximum dosage. The
four CAGE screening questions for alcoholism were
included, in which a score of 2-4 is considered a
positive screen.'*
Psychological variables included the number of
reported psychological benefits (range 0-6) from
taking AASs (really felt good, felt 'high' or extreme
pleasure, felt more confident, felt more aggressive,
improved sex life, attracted new sex partners), the
degree of satisfaction with one's body and physical
appearance before and after using AASs, and the
degree of feeling 'not big enough' before and after
using AASs. The following adverse effects were also
studied: presence of psychotic symptoms (saw
things or heard voices that were not really there;
believed things were happening that really were not)
and the number of aggressive symptoms (range 0-4)
(more aggressive, more irritable, more angry out-
bursts, and more violent confrontations). Because
aggression is sometimes considered a benefit and
sometimes a side effect by AAS users, the question-
naire listed this effect under both categories.
Finally, the following physical variables were
assessed: the number of reported physical benefits
(range 0-6) from taking AASs (increased muscle
strength, increased muscle size, increased endurance
during workouts, increased performances during
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competition, competed with better athletes than
before, improved recovery time after injury); the
difference in body weight before and after using
AASs; and the increase in the maximum amount of
weight lifted before and after using AASs for both
the bench press (upper extremity strength) and the
squat (lower extremity strength). The total number
(range 0-19) of adverse side effects was also
compared, including 11 physical effects (musculo-
skeletal injuries, testicular atrophy, gynecomastia,
insomnia, acne, edema, hirsutism, alopecia, jaun-
dice, liver disease, hypertension) and eight psycho-
logical ones (more aggressive, more irritable, more
angry outbursts, more violent confrontations, hallu-
cinations, delusions, increased or decreased libido).
Data analysis
Our primary interest was in predicting dependence
using a multiple regression analysis. As preliminary
steps, we conducted univariate analyses, both for
descriptive purposes and to eliminate variables from
the multiple regression analysis.
Primarily for descriptive purposes, we compared
the dependent and non-dependent groups of sub-
jects in terms of the four major domains of variables
(Table 4). For these comparisons, t tests were
applied for continuous variables. Dichotomous vari-
ables were tested with either the chi-square test or
the Fisher's exact test if cell sizes were too small.
Ordinal variables were tested with the Wilcoxon
two-sample test. All tests were two-tailed. Nominal
significance levels were determined and presented.
The experiment-wise significance levels (Bonfer-
roni corrections) were calculated, based on the
number of comparisons within each domain of
variables, and are mentioned in the results where
they were important.
Because severity of drug dependence may be
considered a continuum and because the DSM-III-
R's threshold value of three symptoms for depen-
dence is somewhat arbitrary, we used the number of
positive DSM-III-R criteria for each subject as our
next variable of interest. Correlation tests were
performed between the number of dependency
symptoms and other variables, using Pearson r
and Spearman (r,) rank-order correlations for con-
tinuous and ordinal variables, respectively.
Finally, we employed stepwise, multiple regres-
sion techniques to evaluate the simultaneous impact
of the independent variables on the number of
positive criteria for drug dependence. The correla-
tions previously described were utilized to reduce
the number of variables considered for the regres-
sion model. Those variables that suggested a poten-
tial association (/)<0.10) were entered into the
multiple regression analysis.
Results
Characteristics of the sample
In general, subjects were young, single, white men
who were employed and had completed over 2 years
of college (Table 1). Subjects had been lifting
weights for a mean of 88.1 (±52.3) months and
spent a mean of 10.6 ( ± 3.9) hours each week lifting
weights. Their most commonly cited reasons for
lifting weights were to improve physical appearance
(96%), to improve physical condition (92%), for
personal enjoyment (92%), and to increase self-
esteem (89%). By contrast, only 57% of the sample
were lifting weights to train for sporting events and
only 44% were specifically training for bodybuilding
competition (Table 1). One-fifth (19.6%) of the
sample denied training for either bodybuilding
competition or other sports.
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To improve physical appearance
To improve physical condition
Por personal enjoyment
To increase self-esteem
To increase energy level
To attract sexual partners

















t Subjects could endorse more than one reason.
Subjects began using AASs at a mean age of 21.2
(±4.3) years, and had been lifting weights for a
mean of 4.0 ( ± 3.0) years before initiating AASs.
The mean interval (duration) between first and last
use of AASs was 20.9 ( ± 25.2) months. Sixty-one
(60.9%) percent of the sample used both injectable
and oral AASs, while 19.6% each used either
injectable or oral agents exclusively. Thus, approxi-
mately 80% had injected AASs, but all subjects
denied sharing needles. A pattern of use character-
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* Representative trade names, not necessarily taken by subjects.
t See text for method of estimation.
X Units for oxymetholone only are mg/kg/wk.
§ Injectable drug form. Finaject 30 might also signify bolasterone to some users.
11 Veterinary drug for which human dosage is unknown.
ized by 'cycling' (periods of use followed by periods
of no use) was practiced by 73.5% of the sample.
The most commonly used AASs by our sample are
listed in Table 2. The mean weekly doses used for
each of the AASs are compared to 'average'
therapeutic doses, defined as the mathematical mean
of the range of therapeutic doses as cited in an
authoritative textbook of pharmacology." (For
example, the therapeutic dosage range for testo-
sterone cypionate is 50-400 mg every 2-4 weeks."
The mathematical mean is 225 mg every 3 weeks or
75 mg per week.) Subjects exceeded therapeutic
dosages for each of the commonly used AASs by 2-
to 26-fold. Because subjects combined or 'stacked' a
mean of 2.6 (±1.2) AASs at one time, individual
subjects may have exceeded therapeutic dosages by
even more.
Symptoms of dependence
All nine DSM-III-R criterion symptoms for depen-
dence were reported (Table 3). The mean number
of DSM-III-R symptoms of dependence reported
was 2.8 (±1.6). At least one symptom of depen-
dence was reported by 94% of the sample. Three or
more symptoms, consistent with a DSM-III-R
diagnosis of dependence, were reported by 28 (57%)
of the subjects. Four (8.2%) of the subjects
endorsed six or more symptoms and, thus, might be
classified with severe dependence as described in
DSM-III-R.
Withdrawal was the most commonly reported
symptom of dependence (84%). The most fre-
quently reported withdrawal symptoms were de-
pressive in nature: fatigue (43%), depressed mood
(41%), restlessness (29%), anorexia (24%), insom-
nia (20%), and decreased libido (20%). Other
frequently reported symptoms during withdrawal
were: a desire to take more AASs (52%), dissatisfac-
tion with body image (42%), and headaches (20%).
Suicidal thoughts were reported by 4% of the group
during the withdrawal period.
Correlates of dependence
Of the 49 AAS users, 28 were classified as
dependent ( ^ 3 positive DSM-III-R criteria) and
the remaining 21 were non-dependent. Analyses
demonstrated that these groups did not differ
significantly with respect to age, age at first use,
race, education, income, employment status, or
marital status.
Table 4 presents the comparisons between the
dependent and non-dependent groups for the phar-
macological, psychological, and physical variables.
Suggestive differences (nominal/><0.05) were seen
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More substance taken than intended
Desire yet unable to cut down or control use
Large time expenditure on
substance-related activity
Frequent intoxication or withdrawal symptoms when
expected to function or when physically hazardous
Social, work, or leisure activities replaced
by AAS use
Continued AAS use despite problems caused
or worsened by use
Tolerance
Withdrawal symptoms






















* Group size was smaller for some symptoms due to incomplete responses.
for maximum dosage, number of cycles, not feeling
big enough after using AASs, and number of
aggressive symptoms. As might be expected, depen-
dent users took larger doses of AASs, completed
more cycles of use, and reported more aggressive
symptoms. An unexpected finding was that they
continued to feel not big enough after using AASs
(/)<0.0063 after Bonferroni correction). With re-
spect to other substances, there were consistent,
albeit statistically insignificant, trends for the de-
pendent users to drink, smoke, and use stimulants
more (Table 4). Both groups of AAS users had
relatively high rates of alcoholic drinking as deter-
mined by positive CAGE scores, yet extremely low
levels of cigarette consumption. There was a non-
significant trend for more dependent users to report
feeling 'high' on AASs (50 vs 33%).
The correlations between the number of depen-
dency symptoms and the predictor variables are
presented in Table 5. Using an alpha level of 0.10
for entry into the linear regression analysis, the
following variables were selected: number of AASs
tried, maximum dosage, CAGE score, feeling not
big enough before AASs, feeling not big enough
now, dissatisfied with appearance before AASs,
number of aggressive symptoms, difference in body
weight, difference in the amount of weight lifted by
the bench press method (an exercise of upper
extremity strength), and number of adverse side
effects. Although the number of cycles was very
highly correlated with the number of dependency
symptoms, there were 30 missing responses because
the question was omitted from the original version
of the questionnaire. Therefore, this variable was
not used in the subsequent analysis.
Using stepwise techniques, we arrived at the
model presented in Table 6. The significant predic-
tors of the number of dependency symptoms were
maximum dosage of AASs taken and feeling not big
enough after taking AASs. The model implies that
as the maximum dosage increases by 1 SD, the
number of dependency symptoms increases by 0.54,
given that the response to feeling not big enough
remains constant. Likewise, the change from never
to sometimes feeling not big enough, or from
sometimes to always feeling not big enough, predicts
an average of 1.6 more symptoms of dependence,
given that the dosage remains constant.
Discussion
Several other studies have described AAS users who,
similar to our sample, were either all or predomi-
nantly male,''*'""^" were relatively young,''*''*-""^"
used higher than therapeutic does,*'"-'*, combined
or 'stacked' multiple AASs,''*-"-^', 'cycled',''"'^'
used veterinary preparations,'-*-^" and had high rates
of alcohol abuse.' Furthermore, our list and ranking
of the most commonly used AASs (Table 2) are
nearly identical to those reported recently by two
other independent research teams in different geo-
graphical locations.'-^' Also, the time lag between
initiating weight lifting and starting to use AASs was
4-6 years in another recent study,^'' compared to a
mean of 4.0 years in our sample. Finally, our
subjects, similar to others,'-"-" reported getting
bigger and stronger after using AASs. Although the
physical gains reported by our subjects were not
objectively verified, and although the true efficacy
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Number of AASs tried
Number of AASs combined
Duration of use (months)
Number of 'cycles' (episodes of use)
Length of cycles (weeks)
Injectables used (%)
Maximum dosage (^-score)
Other performance aids tried (no.)
Cocaine/amphetamine use (%)
Cigarette use (pack-years)
Max drinks/day in last 30 days
CAGE score positive (>:2) (%)
Psychological
Psychological benefits (0-6)
Felt 'high' on steroids (%)
Satisfied with appearance before 11
Satisfied with appearance after| |
Felt not big enough beforeH
Feels not big enough nowl
Psychotic symptoms reported (%)
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* Continuous variables are expressed as means ( ± SD) and compared by Student's t-tests; dichotomous variables are
expressed as percent positive and compared by chi-square tests unless otherwise specified.
t Group sizes are smaller for some variables due to incomplete responses.
t Fisher's exact test (two-tailed) was used because of small cell sizes.
§ Wilcoxon two-sample tests were used for median scores.
II Median score (before or after steroids) on a scale of 1-4 with 1 signifying least satisfaction.
H Median score (before or after steroids) on a scale of 1-5 with 1 signifying never feeling not big enough and 5 signifying
feeling not big enough all of the time.
of AASs in producing these desired effects remains
controversial,' the perception of users that these
drugs work must be taken into account by any
program of prevention or treatment.
Symptoms of dependence, based on DSM-III-R
criteria, were commonly reported. At least one
symptom of dependence was reported by 94% of the
samplej and three or more symptoms, consistent
with a DSM-III-R diagnosis of dependence, were
reported by 57%. All dimensions of the dependency
syndrome, including symptoms of both psychologi-
cal dependence (symptoms 1-6) and physical de-
pendence (symptoms 7-9), were reported with the
use of AASs (Table 3).
The discrepancy between the high frequency of
withdrawal symptoms (84%) and the low use of
AASs to relieve withdrawal symptoms (4%) re-
quires explanation. The discrepancy may be attribu-
table to the way the questions were asked. After a
checklist of various withdrawal symptoms, subjects
were asked, "Have you often used steroids to keep
yourself from getting sick or have you often used
steroids when you were feeling sick so that you
would feel better?" The wording for this question is
nearly identical to the corresponding question in the
Structured Clinical Interview for DSM-III-R."
Nevertheless, had the question referred directly
back to the list of withdrawal symptoms, the
frequency of positive responses may have been
higher.
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Table 5. Correlations between number of dependency symptoms and other variables
Variable
Pharmacologic
Number of AASs tried
Number of AASs combined
Maximum dosage (2-score)
Number of 'cycles' (episodes of use)
Length of cycles
Duration of use
Other performance aids tried
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* Pearson r correlations are presented except where noted otherwise,
t Spearman rank-order correlation coefficient (r,).
XP<O.QS which is considered a significant correlation.
§/)<0.10 which qualified variable for multiple regression analysis.




Feels not big enough
number of dependency symptoms.
















When comparisons were made between depen-
dent («=28) and non-dependent (n=21) users,
only pharmacologic and psychological variables
were nominally significant. As might be expected,
dependent users had taken larger doses of AASs and
had completed more cycles of use. They also were
more likely to feel not big enough, and they reported
more aggressive symptoms (Table 4). Interestingly,
the number of aggressive symptoms did not corre-
late with the maximum dose (rs=0.054,/)=0.76) or
with any other pharmacological variables, including
other substance use (data not shown). Although the
severity of aggressive symptoms was not assessed
and may have been dose-related, these data raise the
possibility that non-pharmacological factors (such
as an underlying psychological vulnerability) may
predispose steroid users to aggressivity with AASs.
Clinically, dependence on AASs should be sus-
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pected in users who manifest aggressive symptoms
or who persist in AAS-taking despite aggressive
problems.
In the multiple regression analysis, larger doses
and feeling not big enough were predictors of
dependence. These findings are consistent with a
model we have proposed previously.^ In that model,
we postulated that progression from initial use of
AASs to dependent use of AASs was likely to be
influenced by pharmacological, psychiatric, and
genetic factors. Of particular interest is the finding
that dependent users did not feel big enough despite
their reports of getting physically bigger on AASs.
Thus, body size dissatisfaction may represent a
psychological vulnerability that predisposes AAS-
takers to dependence. The situation may be some-
what analogous, although in reverse fashion, to
patients with anorexia nervosa, who persistently
employ (or are 'dependent' on) dieting and other
weight-loss measures because they do not feel small
enough despite getting physically smaller. More-
over, preliminary data from our steroid non-users
revealed greater dissatisfaction with body size
among the non-users who were thinking about using
AASs, compared to non-users who were not think-
ing about using.^^ One clinical implication is that
attention to body image may be crucial for both
prevention and treatment efforts with respect to
AASs.
Two pertinent variables, having no significant
correlations with dependency symptoms, were age
at first use and other substance use. Ag'e at first use
has been shown to be an important predictor of
problematic use of alcohol and other dnigs.^'
Similarly, Yesalis et al}* found that senior high
school students who began using AASs before the
age of 16 years were more likely to manifest
symptoms of 'psychological dependence'. The lack
of a correlation in this study may relate to the small
variance in our sample for age at first use. With
respect to other substances, our sample had a high
rate of alcoholic drinking, similar to the finding by
Perry et al.^ in their diagnostic study of both
steroid-using and non-using weight lifters. The
sharp contrast between high alcohol consumption
and low cigarette use in our sample is an interesting
pattern, because in most other instances cigarette
and alcohol consumption are highly correlated with
each other.^' The way in which alcohol, cigarettes,
and AASs are differentially viewed by this group
may provide a key for influencing the use (or lack of
use) of AASs among weight lifters. Apparently,
weight lifters have values and beliefs that discourage
cigarette smoking. One can speculate on the nature
of these beliefs, such as "smoking will impair my
athletic performance", "smoking will detract from
my physical appearance", "smoking will cause me
physical harm" or "smoking cigarettes is addicting".
To the extent that research both confirms that
weight lifters have these beliefs and provides
evidence that these are appropriate beliefs to have
about AASs as well, then research-based education
might help to deter steroid-taking. Indeed, existing
research already provides some evidence that taking
AASs may (1) increase tendon injuries which could
impair athletic performance,^' (2) detract from
physical appearance by causing unsightly acne and
gynecomastia,'-^' (3) cause physical harm,'-^* and
(4) lead to addiction.'*''-'" Nevertheless, in contrast
to tobacco smoking, epidemiological studies of the
long-term health consequences of using AASs are
completely lacking.^' In the absence of such studies,
prevention programs must be careful to avoid using
scare tactics that will lack credibility to potential
users. In any case, the relationship between AAS
dependence and other substance dependence war-
rants further study.
Some authors have speculated that AASs may
affect either endogenous opioid or monoaminergic
systems in the brain to produce dependence.^'''"*
Although we did not study neurotransmitter sys-
tems, drug-induced euphoria may be an indirect
measure of neurotransmitter-mediated reinforce-
ment. One-half of the dependent users reported
feeling high or extreme pleasure on AASs (Table 4),
suggesting that AASs can reinforce self-administra-
tion in part by euphorigenic properties. Neverthe-
less, the other half did not report euphoria, and
euphoria did not correlate with dependence.
Other authors have suggested that AAS depen-
dence develops in response to the social reinforce-
ment and pleasure from having a big muscular
body.^* Although we did not inquire about social
reinforcement per se, neither psychological benefits
(including the ability to attract new sexual partners
and improved sex life) nor physical benefits corre-
lated with dependence. Indeed, dependent users
were more likely to express dissatisfaction rather
than pleasure with their bodies. In short, our data
suggest that addiction to AASs is driven more by
negative reinforcement (trying to avoid feeling not
big) than by positive reinforcement (psychological
and physical benefits).
There are several methodological limitations to
this study. First is the issue of selection bias. We
relied on convenience to recruit subjects from a
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small number of gyms, which were located within a
relatively restricted geographic region. Thus, we do
not know how representative our sample was of other
AAS users, particularly women. Moreover, we can
make no generalizable prevalence statements regard-
ing AAS dependence. We do believe, however, that the
study demonstrates that dependence on AASs occurs
commonly enough to be readily detectable with the
methods we employed. The fact that our sample was
drawn from the community, rather than from a
treatment setting, makes the high prevalence of
dependence in this study all the more striking.
A second limitation is the lack of methods to
corroborate self-report, such as direct interviews,
physical measurements, or urine testing. We did
pilot the instrument as previously described and
included internal reliability measures. In addition,
the use of anonymous self-report may have facili-
tated truthful responding. Nevertheless, the find-
ings of this study should be confirmed by similar
studies in which corroborating information is ob-
tained. Finally, there were a number of potentially
pertinent variables that were not explored here.
Future studies should include genetic or fami-
lial factors, such as a family history of substance
abuse, and predisposing psychopathology such as
sociopathy or depression. Such studies should also
more clearly define the variable of 'feeling not big
enough', which could refer to weight, muscularity,
and/or height. Future research could also employ a
prospective design, in which a larger cohort of AAS-
using initiates are followed over time, until a
proportion of them become dependent.
Conclusions
The full spectrum of dependency symptoms was
reported by our sample of AAS users. The knowl-
edge that the use of AASs can lead to dependence
may discourage some at-risk individuals from initi-
ating use. Thus, this information may have value to
those involved in prevention efforts. Prevention
' programs might also benefit by research into the
reasons for the dissociation we found between heavy
alcohol and minimal tobacco use. If confirmed by
other studies, then the protective factors against
smoking among AAS users might be 'harnessed' in
the service of preventing AAS use and heavy alcohol
consumption among this population. Dependent
users reported more symptoms of aggression than
non-dependent users, underscoring the clinical im-
portance of diagnosing and treating dependence
among aggressive AAS users. Moreover, the number
of aggressive symptoms did not correlate with
dosage or other pharmacological variables, suggest-
ing that a non-pharmacological factor (such as a
psychological vulnerability) may predispose AAS
users to aggressiveness. Finally, the best predictors
of dependence were dosage and dissatisfaction with
body size. Both prevention and treatment programs,
therefore, may need to target body image in order to
be optimally effective.
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